Prostate News Archive
26-Feb-2008
GTx's Toremifene Citrate 80 mg Meets Primary and Key Endpoints in Phase III Trial in Advanced Prostate Cancer Patients ... (Centre Daily Times)
GTx, Inc. (NASDAQ:GTXI) today announced Phase III clinical data for toremifene citrate 80 mg, the Company's investigational therapy for the treatment of multiple side effects of androgen deprivation therapy (ADT) for advanced prostate cancer. Results show that toremifene citrate 80 mg reduced vertebral fractures and met other key endpoints, including bone mineral density, lipid profiles, and ... OHSU Cancer Institute research gives hope for chemo holidays for men with advanced prostate cancer (EurekAlert!)
PORTLAND, Ore. ? Oregon Health & Science University Cancer Institute researchers, in a first-of-its-kind study, have found that even men with advanced prostate cancer can take a much-needed safe break, or holiday, from chemotherapy. Men need Internet help to get prostate cancer info (Reuters via Yahoo! News)
Visiting Web sites that provide general patient information on prostate cancer is not the best way for men to get help deciding whether to be screened for the disease, a new study shows.
Back to Prostate News Archive
